Conversely, inhibitors of kynurenine aminotransferase II (KATII), which act to block the conversion of L‐kynurenine (L‐KYN) into KYNA, offer a distinct avenue for reducing cognitive deficits in COVID‐19 patients by directly lowering KYNA levels [107]. The gene discussed is AADAT; the disease is COVID-19.